Dr. David Bursill
Consultant rheumatologist and gout nomenclature researcher
Gout • hyperuricemia • crystal-associated disease nomenclature • treat-to-target therapy • under-treatment of inflammatory arthritis
About the expert
Focus: Standardizing gout nomenclature and closing the gout under-treatment gap
Consultant Rheumatologist at Royal Adelaide Hospital and the University of Adelaide, South Australia. Lead author and nomenclature research fellow on the Gout, Hyperuricemia and Crystal-Associated Disease Network consensus statement defining labels and definitions across the crystal arthropathy spectrum. Originally a general practitioner who completed specialist rheumatology training including research experience in New Zealand. Active in patient education through The Hospital Research Foundation webinars.
Why this matters
Consultant rheumatologist and crystal-disease nomenclature researcher. Tends to view gout as a chronic metabolic disease that is highly treatable when approached systematically with treat-to-target urate-lowering therapy, and argues forcefully that the biggest barrier is the persistent under-treatment gap rather than the difficulty of treatment itself. Strongest on gout management discipline and crystal-disease nomenclature; less involved in broader rheumatology or non-crystal arthritis research.